Kedrion Biopharma is a biopharmaceutical company that specializes in the development, production, and distribution of plasma-derived products for the treatment of rare and serious diseases. The company's product portfolio includes immunoglobulins, coagulation factors, and albumin, which are used to treat a variety of conditions, including immune deficiencies, bleeding disorders, and shock. Kedrion Biopharma operates in more than 100 countries worldwide and has a strong presence in Europe, North America, and Asia. The company is committed to improving the lives of patients with rare and serious diseases by providing high-quality, safe, and effective therapies. Kedrion Biopharma is headquartered in Fort Lee, New Jersey.